nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolasetron—CYP2C9—Teniposide—lymphatic system cancer	0.175	0.35	CbGbCtD
Dolasetron—CYP3A4—Cytarabine—lymphatic system cancer	0.104	0.207	CbGbCtD
Dolasetron—CYP3A4—Teniposide—lymphatic system cancer	0.102	0.203	CbGbCtD
Dolasetron—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0713	0.142	CbGbCtD
Dolasetron—CYP3A4—Vincristine—lymphatic system cancer	0.0491	0.0979	CbGbCtD
Dolasetron—Myalgia—Fludarabine—lymphatic system cancer	0.00183	0.00367	CcSEcCtD
Dolasetron—Discomfort—Fludarabine—lymphatic system cancer	0.00181	0.00363	CcSEcCtD
Dolasetron—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00179	0.00359	CcSEcCtD
Dolasetron—Dyspnoea—Teniposide—lymphatic system cancer	0.00178	0.00357	CcSEcCtD
Dolasetron—Pneumonia—Carmustine—lymphatic system cancer	0.00177	0.00355	CcSEcCtD
Dolasetron—Confusional state—Fludarabine—lymphatic system cancer	0.00177	0.00355	CcSEcCtD
Dolasetron—Dysuria—Vincristine—lymphatic system cancer	0.00176	0.00353	CcSEcCtD
Dolasetron—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00175	0.00352	CcSEcCtD
Dolasetron—Oedema—Fludarabine—lymphatic system cancer	0.00175	0.00352	CcSEcCtD
Dolasetron—Decreased appetite—Teniposide—lymphatic system cancer	0.00174	0.00348	CcSEcCtD
Dolasetron—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00172	0.00344	CcSEcCtD
Dolasetron—Stomatitis—Carmustine—lymphatic system cancer	0.00172	0.00344	CcSEcCtD
Dolasetron—Rash—Mechlorethamine—lymphatic system cancer	0.00171	0.00342	CcSEcCtD
Dolasetron—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00171	0.00342	CcSEcCtD
Dolasetron—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.0017	0.0034	CcSEcCtD
Dolasetron—Pneumonia—Vincristine—lymphatic system cancer	0.00169	0.00339	CcSEcCtD
Dolasetron—Flushing—Bleomycin—lymphatic system cancer	0.00168	0.00337	CcSEcCtD
Dolasetron—Anorexia—Fludarabine—lymphatic system cancer	0.00167	0.00335	CcSEcCtD
Dolasetron—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00166	0.00332	CcSEcCtD
Dolasetron—Myocardial infarction—Vincristine—lymphatic system cancer	0.00165	0.0033	CcSEcCtD
Dolasetron—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00165	0.0033	CcSEcCtD
Dolasetron—Feeling abnormal—Teniposide—lymphatic system cancer	0.00165	0.0033	CcSEcCtD
Dolasetron—Stomatitis—Vincristine—lymphatic system cancer	0.00164	0.00328	CcSEcCtD
Dolasetron—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00164	0.00328	CcSEcCtD
Dolasetron—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00163	0.00327	CcSEcCtD
Dolasetron—Chills—Bleomycin—lymphatic system cancer	0.00162	0.00326	CcSEcCtD
Dolasetron—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00161	0.00324	CcSEcCtD
Dolasetron—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.0016	0.00322	CcSEcCtD
Dolasetron—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.0016	0.00321	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.0016	0.0032	CcSEcCtD
Dolasetron—Stomatitis—Mitoxantrone—lymphatic system cancer	0.0016	0.0032	CcSEcCtD
Dolasetron—Jaundice—Mitoxantrone—lymphatic system cancer	0.0016	0.0032	CcSEcCtD
Dolasetron—Urticaria—Teniposide—lymphatic system cancer	0.00159	0.00318	CcSEcCtD
Dolasetron—Oliguria—Methotrexate—lymphatic system cancer	0.00158	0.00317	CcSEcCtD
Dolasetron—Abdominal pain—Teniposide—lymphatic system cancer	0.00158	0.00316	CcSEcCtD
Dolasetron—Body temperature increased—Teniposide—lymphatic system cancer	0.00158	0.00316	CcSEcCtD
Dolasetron—Paraesthesia—Fludarabine—lymphatic system cancer	0.00158	0.00316	CcSEcCtD
Dolasetron—Dyspnoea—Fludarabine—lymphatic system cancer	0.00156	0.00314	CcSEcCtD
Dolasetron—Haematuria—Mitoxantrone—lymphatic system cancer	0.00156	0.00313	CcSEcCtD
Dolasetron—Oedema peripheral—Carmustine—lymphatic system cancer	0.00156	0.00312	CcSEcCtD
Dolasetron—Dyspepsia—Fludarabine—lymphatic system cancer	0.00154	0.0031	CcSEcCtD
Dolasetron—Decreased appetite—Fludarabine—lymphatic system cancer	0.00153	0.00306	CcSEcCtD
Dolasetron—Visual impairment—Carmustine—lymphatic system cancer	0.00152	0.00305	CcSEcCtD
Dolasetron—Fatigue—Fludarabine—lymphatic system cancer	0.00151	0.00303	CcSEcCtD
Dolasetron—Constipation—Fludarabine—lymphatic system cancer	0.0015	0.00301	CcSEcCtD
Dolasetron—Pain—Fludarabine—lymphatic system cancer	0.0015	0.00301	CcSEcCtD
Dolasetron—Bradycardia—Mitoxantrone—lymphatic system cancer	0.0015	0.003	CcSEcCtD
Dolasetron—Hypersensitivity—Teniposide—lymphatic system cancer	0.00147	0.00295	CcSEcCtD
Dolasetron—Flushing—Carmustine—lymphatic system cancer	0.00147	0.00294	CcSEcCtD
Dolasetron—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00146	0.00293	CcSEcCtD
Dolasetron—Anaemia—Bleomycin—lymphatic system cancer	0.00146	0.00292	CcSEcCtD
Dolasetron—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00145	0.0029	CcSEcCtD
Dolasetron—Asthenia—Teniposide—lymphatic system cancer	0.00143	0.00287	CcSEcCtD
Dolasetron—Malaise—Bleomycin—lymphatic system cancer	0.00142	0.00285	CcSEcCtD
Dolasetron—Pruritus—Teniposide—lymphatic system cancer	0.00141	0.00283	CcSEcCtD
Dolasetron—Arrhythmia—Carmustine—lymphatic system cancer	0.00141	0.00283	CcSEcCtD
Dolasetron—Body temperature increased—Fludarabine—lymphatic system cancer	0.00139	0.00278	CcSEcCtD
Dolasetron—Cough—Bleomycin—lymphatic system cancer	0.00138	0.00276	CcSEcCtD
Dolasetron—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00137	0.00274	CcSEcCtD
Dolasetron—Diarrhoea—Teniposide—lymphatic system cancer	0.00137	0.00274	CcSEcCtD
Dolasetron—Chest pain—Bleomycin—lymphatic system cancer	0.00134	0.00269	CcSEcCtD
Dolasetron—Myalgia—Bleomycin—lymphatic system cancer	0.00134	0.00269	CcSEcCtD
Dolasetron—Discomfort—Bleomycin—lymphatic system cancer	0.00133	0.00266	CcSEcCtD
Dolasetron—Chills—Mitoxantrone—lymphatic system cancer	0.00132	0.00264	CcSEcCtD
Dolasetron—Urine output increased—Methotrexate—lymphatic system cancer	0.00132	0.00264	CcSEcCtD
Dolasetron—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00131	0.00263	CcSEcCtD
Dolasetron—Confusional state—Bleomycin—lymphatic system cancer	0.0013	0.0026	CcSEcCtD
Dolasetron—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00129	0.00259	CcSEcCtD
Dolasetron—Tremor—Carmustine—lymphatic system cancer	0.00129	0.00258	CcSEcCtD
Dolasetron—Oedema—Bleomycin—lymphatic system cancer	0.00129	0.00258	CcSEcCtD
Dolasetron—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00129	0.00258	CcSEcCtD
Dolasetron—Anaemia—Carmustine—lymphatic system cancer	0.00127	0.00255	CcSEcCtD
Dolasetron—Sepsis—Methotrexate—lymphatic system cancer	0.00127	0.00254	CcSEcCtD
Dolasetron—Agitation—Carmustine—lymphatic system cancer	0.00126	0.00254	CcSEcCtD
Dolasetron—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00126	0.00253	CcSEcCtD
Dolasetron—Asthenia—Fludarabine—lymphatic system cancer	0.00126	0.00252	CcSEcCtD
Dolasetron—Rash—Teniposide—lymphatic system cancer	0.00126	0.00252	CcSEcCtD
Dolasetron—Dermatitis—Teniposide—lymphatic system cancer	0.00126	0.00252	CcSEcCtD
Dolasetron—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00125	0.00251	CcSEcCtD
Dolasetron—Headache—Teniposide—lymphatic system cancer	0.00125	0.00251	CcSEcCtD
Dolasetron—Pruritus—Fludarabine—lymphatic system cancer	0.00124	0.00249	CcSEcCtD
Dolasetron—Anorexia—Bleomycin—lymphatic system cancer	0.00123	0.00246	CcSEcCtD
Dolasetron—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00122	0.00245	CcSEcCtD
Dolasetron—Anaemia—Vincristine—lymphatic system cancer	0.00121	0.00243	CcSEcCtD
Dolasetron—Agitation—Vincristine—lymphatic system cancer	0.00121	0.00242	CcSEcCtD
Dolasetron—Polyuria—Methotrexate—lymphatic system cancer	0.00121	0.00242	CcSEcCtD
Dolasetron—Hypotension—Bleomycin—lymphatic system cancer	0.0012	0.00241	CcSEcCtD
Dolasetron—Diarrhoea—Fludarabine—lymphatic system cancer	0.0012	0.00241	CcSEcCtD
Dolasetron—Convulsion—Carmustine—lymphatic system cancer	0.00119	0.00239	CcSEcCtD
Dolasetron—Hypertension—Carmustine—lymphatic system cancer	0.00119	0.00238	CcSEcCtD
Dolasetron—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00119	0.00238	CcSEcCtD
Dolasetron—Anaemia—Mitoxantrone—lymphatic system cancer	0.00118	0.00237	CcSEcCtD
Dolasetron—Vertigo—Vincristine—lymphatic system cancer	0.00118	0.00237	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00117	0.00235	CcSEcCtD
Dolasetron—Myalgia—Carmustine—lymphatic system cancer	0.00117	0.00235	CcSEcCtD
Dolasetron—Chest pain—Carmustine—lymphatic system cancer	0.00117	0.00235	CcSEcCtD
Dolasetron—Anxiety—Carmustine—lymphatic system cancer	0.00117	0.00234	CcSEcCtD
Dolasetron—Paraesthesia—Bleomycin—lymphatic system cancer	0.00116	0.00232	CcSEcCtD
Dolasetron—Malaise—Mitoxantrone—lymphatic system cancer	0.00115	0.00231	CcSEcCtD
Dolasetron—Dyspnoea—Bleomycin—lymphatic system cancer	0.00115	0.0023	CcSEcCtD
Dolasetron—Renal failure acute—Methotrexate—lymphatic system cancer	0.00115	0.0023	CcSEcCtD
Dolasetron—Convulsion—Vincristine—lymphatic system cancer	0.00114	0.00228	CcSEcCtD
Dolasetron—Hypertension—Vincristine—lymphatic system cancer	0.00113	0.00227	CcSEcCtD
Dolasetron—Confusional state—Carmustine—lymphatic system cancer	0.00113	0.00227	CcSEcCtD
Dolasetron—Oedema—Carmustine—lymphatic system cancer	0.00112	0.00225	CcSEcCtD
Dolasetron—Decreased appetite—Bleomycin—lymphatic system cancer	0.00112	0.00224	CcSEcCtD
Dolasetron—Myalgia—Vincristine—lymphatic system cancer	0.00112	0.00224	CcSEcCtD
Dolasetron—Cough—Mitoxantrone—lymphatic system cancer	0.00112	0.00224	CcSEcCtD
Dolasetron—Convulsion—Mitoxantrone—lymphatic system cancer	0.00111	0.00222	CcSEcCtD
Dolasetron—Rash—Fludarabine—lymphatic system cancer	0.00111	0.00222	CcSEcCtD
Dolasetron—Dermatitis—Fludarabine—lymphatic system cancer	0.00111	0.00222	CcSEcCtD
Dolasetron—Hypertension—Mitoxantrone—lymphatic system cancer	0.0011	0.00221	CcSEcCtD
Dolasetron—Pain—Bleomycin—lymphatic system cancer	0.0011	0.00221	CcSEcCtD
Dolasetron—Thrombocytopenia—Carmustine—lymphatic system cancer	0.0011	0.0022	CcSEcCtD
Dolasetron—Headache—Fludarabine—lymphatic system cancer	0.0011	0.0022	CcSEcCtD
Dolasetron—Tachycardia—Carmustine—lymphatic system cancer	0.0011	0.0022	CcSEcCtD
Dolasetron—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00109	0.00219	CcSEcCtD
Dolasetron—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00109	0.00218	CcSEcCtD
Dolasetron—Myalgia—Mitoxantrone—lymphatic system cancer	0.00109	0.00218	CcSEcCtD
Dolasetron—Chest pain—Mitoxantrone—lymphatic system cancer	0.00109	0.00218	CcSEcCtD
Dolasetron—Anxiety—Mitoxantrone—lymphatic system cancer	0.00109	0.00218	CcSEcCtD
Dolasetron—Discomfort—Mitoxantrone—lymphatic system cancer	0.00108	0.00216	CcSEcCtD
Dolasetron—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00107	0.00215	CcSEcCtD
Dolasetron—Oedema—Vincristine—lymphatic system cancer	0.00107	0.00215	CcSEcCtD
Dolasetron—Anorexia—Carmustine—lymphatic system cancer	0.00107	0.00215	CcSEcCtD
Dolasetron—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00106	0.00213	CcSEcCtD
Dolasetron—Confusional state—Mitoxantrone—lymphatic system cancer	0.00105	0.00211	CcSEcCtD
Dolasetron—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00105	0.0021	CcSEcCtD
Dolasetron—Hypotension—Carmustine—lymphatic system cancer	0.00105	0.0021	CcSEcCtD
Dolasetron—Oedema—Mitoxantrone—lymphatic system cancer	0.00104	0.00209	CcSEcCtD
Dolasetron—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00104	0.00209	CcSEcCtD
Dolasetron—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00104	0.00208	CcSEcCtD
Dolasetron—Shock—Mitoxantrone—lymphatic system cancer	0.00103	0.00206	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00102	0.00205	CcSEcCtD
Dolasetron—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00102	0.00205	CcSEcCtD
Dolasetron—Urticaria—Bleomycin—lymphatic system cancer	0.00102	0.00205	CcSEcCtD
Dolasetron—Anorexia—Vincristine—lymphatic system cancer	0.00102	0.00205	CcSEcCtD
Dolasetron—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00102	0.00204	CcSEcCtD
Dolasetron—Body temperature increased—Bleomycin—lymphatic system cancer	0.00102	0.00204	CcSEcCtD
Dolasetron—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00101	0.00202	CcSEcCtD
Dolasetron—Paraesthesia—Carmustine—lymphatic system cancer	0.00101	0.00202	CcSEcCtD
Dolasetron—Hypotension—Vincristine—lymphatic system cancer	0.001	0.00201	CcSEcCtD
Dolasetron—Dyspnoea—Carmustine—lymphatic system cancer	0.001	0.00201	CcSEcCtD
Dolasetron—Somnolence—Carmustine—lymphatic system cancer	0.000998	0.002	CcSEcCtD
Dolasetron—Anorexia—Mitoxantrone—lymphatic system cancer	0.000995	0.002	CcSEcCtD
Dolasetron—Ataxia—Methotrexate—lymphatic system cancer	0.000995	0.002	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000977	0.00196	CcSEcCtD
Dolasetron—Decreased appetite—Carmustine—lymphatic system cancer	0.000976	0.00196	CcSEcCtD
Dolasetron—Hypotension—Mitoxantrone—lymphatic system cancer	0.000975	0.00196	CcSEcCtD
Dolasetron—Paraesthesia—Vincristine—lymphatic system cancer	0.000963	0.00193	CcSEcCtD
Dolasetron—Constipation—Carmustine—lymphatic system cancer	0.00096	0.00193	CcSEcCtD
Dolasetron—Pain—Carmustine—lymphatic system cancer	0.00096	0.00193	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000951	0.00191	CcSEcCtD
Dolasetron—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000948	0.0019	CcSEcCtD
Dolasetron—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000937	0.00188	CcSEcCtD
Dolasetron—Decreased appetite—Vincristine—lymphatic system cancer	0.000932	0.00187	CcSEcCtD
Dolasetron—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000931	0.00187	CcSEcCtD
Dolasetron—Somnolence—Mitoxantrone—lymphatic system cancer	0.000928	0.00186	CcSEcCtD
Dolasetron—Feeling abnormal—Carmustine—lymphatic system cancer	0.000925	0.00186	CcSEcCtD
Dolasetron—Fatigue—Vincristine—lymphatic system cancer	0.000924	0.00185	CcSEcCtD
Dolasetron—Asthenia—Bleomycin—lymphatic system cancer	0.000923	0.00185	CcSEcCtD
Dolasetron—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000919	0.00184	CcSEcCtD
Dolasetron—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000918	0.00184	CcSEcCtD
Dolasetron—Pain—Vincristine—lymphatic system cancer	0.000917	0.00184	CcSEcCtD
Dolasetron—Constipation—Vincristine—lymphatic system cancer	0.000917	0.00184	CcSEcCtD
Dolasetron—Pruritus—Bleomycin—lymphatic system cancer	0.00091	0.00182	CcSEcCtD
Dolasetron—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000907	0.00182	CcSEcCtD
Dolasetron—Fatigue—Mitoxantrone—lymphatic system cancer	0.0009	0.0018	CcSEcCtD
Dolasetron—Pancreatitis—Methotrexate—lymphatic system cancer	0.000897	0.0018	CcSEcCtD
Dolasetron—Pain—Mitoxantrone—lymphatic system cancer	0.000893	0.00179	CcSEcCtD
Dolasetron—Constipation—Mitoxantrone—lymphatic system cancer	0.000893	0.00179	CcSEcCtD
Dolasetron—Abdominal pain—Carmustine—lymphatic system cancer	0.000888	0.00178	CcSEcCtD
Dolasetron—Body temperature increased—Carmustine—lymphatic system cancer	0.000888	0.00178	CcSEcCtD
Dolasetron—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000877	0.00176	CcSEcCtD
Dolasetron—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00086	0.00172	CcSEcCtD
Dolasetron—Dysuria—Methotrexate—lymphatic system cancer	0.000855	0.00171	CcSEcCtD
Dolasetron—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000854	0.00171	CcSEcCtD
Dolasetron—Abdominal pain—Vincristine—lymphatic system cancer	0.000847	0.0017	CcSEcCtD
Dolasetron—Body temperature increased—Vincristine—lymphatic system cancer	0.000847	0.0017	CcSEcCtD
Dolasetron—Urticaria—Mitoxantrone—lymphatic system cancer	0.000829	0.00166	CcSEcCtD
Dolasetron—Hypersensitivity—Carmustine—lymphatic system cancer	0.000827	0.00166	CcSEcCtD
Dolasetron—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000825	0.00165	CcSEcCtD
Dolasetron—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000825	0.00165	CcSEcCtD
Dolasetron—Pneumonia—Methotrexate—lymphatic system cancer	0.00082	0.00164	CcSEcCtD
Dolasetron—Drowsiness—Methotrexate—lymphatic system cancer	0.000816	0.00164	CcSEcCtD
Dolasetron—Rash—Bleomycin—lymphatic system cancer	0.000811	0.00163	CcSEcCtD
Dolasetron—Dermatitis—Bleomycin—lymphatic system cancer	0.00081	0.00162	CcSEcCtD
Dolasetron—Asthenia—Carmustine—lymphatic system cancer	0.000806	0.00162	CcSEcCtD
Dolasetron—Stomatitis—Methotrexate—lymphatic system cancer	0.000795	0.00159	CcSEcCtD
Dolasetron—Hypersensitivity—Vincristine—lymphatic system cancer	0.00079	0.00158	CcSEcCtD
Dolasetron—Haematuria—Methotrexate—lymphatic system cancer	0.000778	0.00156	CcSEcCtD
Dolasetron—Epistaxis—Methotrexate—lymphatic system cancer	0.000769	0.00154	CcSEcCtD
Dolasetron—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000769	0.00154	CcSEcCtD
Dolasetron—Asthenia—Vincristine—lymphatic system cancer	0.000769	0.00154	CcSEcCtD
Dolasetron—Diarrhoea—Carmustine—lymphatic system cancer	0.000768	0.00154	CcSEcCtD
Dolasetron—Asthenia—Mitoxantrone—lymphatic system cancer	0.000749	0.0015	CcSEcCtD
Dolasetron—Dizziness—Carmustine—lymphatic system cancer	0.000743	0.00149	CcSEcCtD
Dolasetron—Diarrhoea—Vincristine—lymphatic system cancer	0.000733	0.00147	CcSEcCtD
Dolasetron—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000714	0.00143	CcSEcCtD
Dolasetron—Dizziness—Vincristine—lymphatic system cancer	0.000709	0.00142	CcSEcCtD
Dolasetron—Rash—Carmustine—lymphatic system cancer	0.000708	0.00142	CcSEcCtD
Dolasetron—Dermatitis—Carmustine—lymphatic system cancer	0.000707	0.00142	CcSEcCtD
Dolasetron—Visual impairment—Methotrexate—lymphatic system cancer	0.000706	0.00141	CcSEcCtD
Dolasetron—Headache—Carmustine—lymphatic system cancer	0.000703	0.00141	CcSEcCtD
Dolasetron—Tinnitus—Methotrexate—lymphatic system cancer	0.000683	0.00137	CcSEcCtD
Dolasetron—Rash—Vincristine—lymphatic system cancer	0.000676	0.00136	CcSEcCtD
Dolasetron—Dermatitis—Vincristine—lymphatic system cancer	0.000675	0.00135	CcSEcCtD
Dolasetron—Headache—Vincristine—lymphatic system cancer	0.000672	0.00135	CcSEcCtD
Dolasetron—Rash—Mitoxantrone—lymphatic system cancer	0.000658	0.00132	CcSEcCtD
Dolasetron—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000658	0.00132	CcSEcCtD
Dolasetron—Chills—Methotrexate—lymphatic system cancer	0.000657	0.00132	CcSEcCtD
Dolasetron—Headache—Mitoxantrone—lymphatic system cancer	0.000654	0.00131	CcSEcCtD
Dolasetron—Dysgeusia—Methotrexate—lymphatic system cancer	0.000624	0.00125	CcSEcCtD
Dolasetron—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000591	0.00119	CcSEcCtD
Dolasetron—Anaemia—Methotrexate—lymphatic system cancer	0.000589	0.00118	CcSEcCtD
Dolasetron—Malaise—Methotrexate—lymphatic system cancer	0.000575	0.00115	CcSEcCtD
Dolasetron—Vertigo—Methotrexate—lymphatic system cancer	0.000573	0.00115	CcSEcCtD
Dolasetron—Cough—Methotrexate—lymphatic system cancer	0.000556	0.00111	CcSEcCtD
Dolasetron—Convulsion—Methotrexate—lymphatic system cancer	0.000552	0.00111	CcSEcCtD
Dolasetron—Myalgia—Methotrexate—lymphatic system cancer	0.000543	0.00109	CcSEcCtD
Dolasetron—Chest pain—Methotrexate—lymphatic system cancer	0.000543	0.00109	CcSEcCtD
Dolasetron—Arthralgia—Methotrexate—lymphatic system cancer	0.000543	0.00109	CcSEcCtD
Dolasetron—Discomfort—Methotrexate—lymphatic system cancer	0.000536	0.00107	CcSEcCtD
Dolasetron—Confusional state—Methotrexate—lymphatic system cancer	0.000524	0.00105	CcSEcCtD
Dolasetron—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00052	0.00104	CcSEcCtD
Dolasetron—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000509	0.00102	CcSEcCtD
Dolasetron—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000503	0.00101	CcSEcCtD
Dolasetron—Anorexia—Methotrexate—lymphatic system cancer	0.000496	0.000994	CcSEcCtD
Dolasetron—Hypotension—Methotrexate—lymphatic system cancer	0.000486	0.000974	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000474	0.00095	CcSEcCtD
Dolasetron—Paraesthesia—Methotrexate—lymphatic system cancer	0.000467	0.000936	CcSEcCtD
Dolasetron—Dyspnoea—Methotrexate—lymphatic system cancer	0.000464	0.00093	CcSEcCtD
Dolasetron—Somnolence—Methotrexate—lymphatic system cancer	0.000462	0.000927	CcSEcCtD
Dolasetron—Dyspepsia—Methotrexate—lymphatic system cancer	0.000458	0.000918	CcSEcCtD
Dolasetron—Decreased appetite—Methotrexate—lymphatic system cancer	0.000452	0.000907	CcSEcCtD
Dolasetron—Fatigue—Methotrexate—lymphatic system cancer	0.000448	0.000899	CcSEcCtD
Dolasetron—Pain—Methotrexate—lymphatic system cancer	0.000445	0.000892	CcSEcCtD
Dolasetron—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000429	0.000859	CcSEcCtD
Dolasetron—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000425	0.000853	CcSEcCtD
Dolasetron—Urticaria—Methotrexate—lymphatic system cancer	0.000413	0.000828	CcSEcCtD
Dolasetron—Abdominal pain—Methotrexate—lymphatic system cancer	0.000411	0.000824	CcSEcCtD
Dolasetron—Body temperature increased—Methotrexate—lymphatic system cancer	0.000411	0.000824	CcSEcCtD
Dolasetron—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000383	0.000768	CcSEcCtD
Dolasetron—Asthenia—Methotrexate—lymphatic system cancer	0.000373	0.000748	CcSEcCtD
Dolasetron—Pruritus—Methotrexate—lymphatic system cancer	0.000368	0.000738	CcSEcCtD
Dolasetron—Diarrhoea—Methotrexate—lymphatic system cancer	0.000356	0.000713	CcSEcCtD
Dolasetron—Dizziness—Methotrexate—lymphatic system cancer	0.000344	0.00069	CcSEcCtD
Dolasetron—Rash—Methotrexate—lymphatic system cancer	0.000328	0.000658	CcSEcCtD
Dolasetron—Dermatitis—Methotrexate—lymphatic system cancer	0.000328	0.000657	CcSEcCtD
Dolasetron—Headache—Methotrexate—lymphatic system cancer	0.000326	0.000653	CcSEcCtD
